Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

...

193

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L04AA52	KESIMPTA	BioTech	Ofatumumab - 20mg/0.4ml	20mg/0.4ml	Injectable solution	L.L
B05CX01	DEXTROSE 20% INJECTION USP	G	Glucose - 20%	20%	Injectable solution	183,869 L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	148,244 L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	148,244 L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	159,736 L.L
B05AA01	ALBUREL HUMAN ALBUMIN BP	BioHuman	Albumin human - 20%	20%	Injectable solution	L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	179,272 L.L
L04AB04	ADALIREL	BioTech	Adalimumab - 40mg	40mg	Injectable solution	L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	191,913 L.L
B03XA01	EPOMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 4000UI/ml	4000UI/ml	Injectable solution	L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	191,913 L.L
L01XX41	HALAVEN	B	Eribulin mesylate - 0.88mg/2ml	0.88mg/2ml	Injectable solution	18,792,549 L.L
L01BB05	FLUDARABINE PHOSPHATE NEAPOLIS	G	Fludarabine Dihydrogenophosphate - 50mg/2ml	50mg/2ml	Injectable solution	L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	208,002 L.L
R03DX05	XOLAIR	BioTech	Omalizumab - 150mg	150mg	Injectable solution	30,766,872 L.L
L01BA04	PEMETREXED NEAPOLIS	G	Pemetrexed (disodium) - 100mg	100mg	Injectable solution	L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	224,090 L.L
N07AA01	METHYL SULFATE DE NEOSTIGMINE RENAUDIN	G	Neostigmine methyl sulfate - 0.5mg/ml	0.5mg/ml	Injectable solution	467,657 L.L
R03DX10	FASENRA	B	Benralizumab - 30mg	30mg	Injectable solution	214,213,273 L.L
B05CX01	5% DEXTROSE INJECTION USP	G	Glucose - 5%	5%	Injectable solution	148,244 L.L
N07AA01	NEOSTIGMINE RENAUDIN	G	Neostigmine - 5mg/5ml	5mg/5ml	Injectable solution	2,460,576 L.L
B05CX01	ALDEX	G	Dextrose, H2O - 5g/100ml	5g/100ml	Injectable solution	174,062 L.L
B05CX01	ALDEX	G	Dextrose, H2O - 5g/100ml	5g/100ml	Injectable solution	174,062 L.L
C03CA01	FRURETIC	G	Furosemide - 20mg/2ml	20mg/2ml	Injectable solution	2,600,655 L.L
M05BA06	BONVIVA	B	Ibandronic acid - 3mg/3ml	3mg/3ml	Injectable solution	3,144,591 L.L
N02BG06	ACUPAN	B	Nefopam HCl - 20mg	20mg	Injectable solution	365,525 L.L
B05CX01	ALDEX	G	Dextrose, H2O - 5g/100ml	5g/100ml	Injectable solution	170,630 L.L
C03CA01	FUROLIX	G	Furosemide - 20mg/2ml	20mg/2ml	Injectable solution	1,612,611 L.L
J06BA02	IG VENA	BioHuman	Human normal immunoglobulin - 2.5g/50ml	2.5g/50ml	Injectable solution	17,011,323 L.L
N02BG06	NEO-PAN	G	Nefopam HCl - 20mg/2ml	20mg/2ml	Injectable solution	483,783 L.L

...

193